{"id":3028,"date":"2013-10-28T12:13:12","date_gmt":"2013-10-28T12:13:12","guid":{"rendered":"\/?p=3028"},"modified":"2013-10-28T12:29:15","modified_gmt":"2013-10-28T12:29:15","slug":"biolife-solutions-inc-otcmktsblfs-caught-in-reverse-current","status":"publish","type":"post","link":"\/articles\/biolife-solutions-inc-otcmktsblfs-caught-in-reverse-current\/","title":{"rendered":"Biolife Solutions, Inc. (OTCMKTS:BLFS) Caught in Reverse Current"},"content":{"rendered":"

Biolife Solutions, Inc. (OTCMKTS:BLFS<\/a>) is yet another biopharmaceutical stunner, which now faced a cliff drop of selling. BLFS<\/a> fell by more than 26% to $1.07, on dollar volumes above $628,000. The rise in BLFS<\/a> was on relatively modest dollar volumes, and we looked at it last in August, when the ticker was a bit below 90 cents. While the rising trend looked good in August, it grew even steeper in September and October, and this made the positions of BLFS<\/a> much shakier. \"BLFS1027.png\" <\/p>\n

BLFS<\/a> has not come in with a promotion or a new press release since the end of September, and what caused the selling is not immediately clear. BLFS<\/a> held great promise for improved earnings in the later half of the year, but the lack of news pushed the shares down. \"ISCO1028.png\"<\/p>\n

The latest mention of treatments in development came at the end of September, when BLFS<\/a> updated on the clinical usage of its proprietary cryopreservation technology. BLFS<\/a> has the major advantage of offering a technology that is essential in may medical fields, instead of aiming for a novel product that may have to wait before being applied in practices.<\/p>\n

BLFS<\/a>, according to its latest filings, is equipped with the following financials:<\/p>\n